- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio | 1 | Investing.com | ||
| 08.12. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | 111 | GlobeNewswire (Europe) | Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension... ► Artikel lesen | |
| 26.11. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 13.11. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews | ||
| 10.11. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | 148 | GlobeNewswire (Europe) | Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital... ► Artikel lesen | |
| 10.11. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Orchestra BioMed files secondary offering of ~8M shares | 2 | Seeking Alpha | ||
| 28.10. | Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB | 5 | RTTNews | ||
| 28.10. | Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement | 2 | MassDevice | ||
| 28.10. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10. | Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial | 1 | MassDevice | ||
| 27.10. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial | 238 | GlobeNewswire (Europe) | Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release... ► Artikel lesen | |
| 09.10. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | 2 | GlobeNewswire (USA) | ||
| 11.09. | Piper Sandler reiterates Overweight rating on Orchestra BioMed stock | 3 | Investing.com | ||
| 11.09. | Piper Sandler bestätigt "Overweight"-Rating für Orchestra BioMed | - | Investing.com Deutsch | ||
| 04.09. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout | 2 | GlobeNewswire (USA) | ||
| 04.09. | Orchestra BioMed stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
| 26.08. | Orchestra BioMed reports positive data on blood pressure therapy | 1 | Investing.com | ||
| 26.08. | Orchestra BioMed meldet positive Studiendaten zu Blutdrucktherapie | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,52 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 4,360 | -3,11 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | +3,55 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.